Karen E. Wood

Learn More
BACKGROUND Currently, metastatic renal cell carcinoma is treated with sequential single agents targeting VEGF or mTOR. Here, we aimed to assess lenvatinib, everolimus, or their combination as second-line treatment in patients with metastatic renal cell carcinoma. METHODS We did a randomised, phase 2, open-label, multicentre trial at 37 centres in five(More)
Total knee arthroplasty (TKA) dramatically decreases pain and improves mobility and quality of life. However, little has been reported on its effect on driving ability in the early postoperative period. This prospective study was conducted to compare preoperative and postoperative brake response times (BRTs) in patients undergoing TKA for osteoarthritis.(More)
Lenvatinib is an oral multi-targeted tyrosine kinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRβ, RET, and KIT. Everolimus is an oral mammalian target of rapamycin inhibitor approved for advanced renal cell carcinoma (RCC). This phase 1b study assessed safety, maximum tolerated dose (MTD), and preliminary antitumor activity of lenvatinib plus everolimus in(More)
Sixty consecutive patients undergoing a primary hybrid total hip arthroplasty were randomized to receive a femoral component either with or without a distal centralizing device. The group with a centralizer had significantly fewer patients with cement mantle deficiencies (excessively thin areas of cement) than the group without a centralizer (P < .001).(More)
In this study, we describe the use of intravital microscopy in a transgenic mouse model expressing yellow fluorescent protein (YFP) under the control of a monocyte specific promoter c-fms (CD115) to track and quantify specific leukocyte subsets. Flow cytometry on peripheral and bone marrow leukocytes revealed that YFP was predominantly expressed by(More)
PURPOSE Receptor tyrosine kinases c-Met and Ron transduce signals regulating cell migration and matrix invasion. This phase I dose-escalation trial tested golvatinib, a highly potent, small-molecule, ATP-competitive inhibitor of c-Met and multiple members of the Eph receptor family plus c-Kit and Ron. EXPERIMENTAL DESIGN Patients with advanced solid(More)
358 Background: Lenvatinib (L) is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR 1-4, RET, KIT, and PDGFβ. Everolimus (E) is an oral mTOR inhibitor approved for RCC. This Phase (Ph) 1b/2 study investigates the combination of L plus E in RCC patients (pts) (NCT01136733). The Ph 1b component reported here assessed safety, tolerability, and maximum(More)
Sympatric speciation is the emergence of new species from a single ancestral species while inhabiting the same geographic region. This process presents an interesting problem for theoretical studies of evolution. One mechanism by which sympatric speciation might occur is periodic or quasiperiodic fluctuations in the abundance of the resources. In this paper(More)
Purpose: Receptor tyrosine kinases c-Met and Ron transduce signals regulating cell migration and matrix invasion. This phase I dose-escalation trial tested golvatinib, a highly potent, small-molecule, ATP-competitive inhibitor of c-Met and multiple members of the Eph receptor family plus c-Kit and